ArticleScientific reports2025
Synergistic effect of synthetic derivatives of 1,3,4-thiadiazole with amphotericin B in antifungal therapy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Aggregation-Modulated Excited-State Intramolecular Proton Transfer and Antifungal Potential of Selected 1,3,4-Thiadiazole Derivatives.International journal of molecular sciences · 2026Article
- Assessment of antimicrobial activity of [1,2,4]triazolo[4, 3-a]quinoxaline derivatives individually and in combination with levofloxacin.Scientific reports · 2026Article
- Evaluation of Antimicrobials Incorporated into Artificial Saliva: Analysis AgainstJournal of functional biomaterials · 2026Article
- Synthesis and characterization of FeCuAlOScientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Amphotericin B (AmB) is a potent antifungal agent with minimal resistance among clinical isolates, but its use is limited by severe side effects. Reducing its toxicity through combination therapy with synergistic compounds is a promising strategy. This study investigates the antifungal potential of 1,3,4-thiadiazole derivatives, focusing on AT2 and AT10, against Candida species. AT2 demonstrated the highest activity, achieving complete inhibition at 128 µg/mL and notable suppression at lower concentrations. The combination of AT2 and AT10 with amphotericin B exhibited synergistic effects, leading to significant structural alterations in the fungal cell wall, including reduced β-glucan levels and increased synthesis of mannan and phosphomannan. These modifications correlated with enhanced antifungal efficacy without exacerbating cytotoxicity toward human fibroblasts and renal epithelial cells. The spectroscopic analysis suggested that the synergy arose from both cell wall disruptions and amphotericin B disaggregation. These findings highlight the potential of thiadiazole-based combination therapies for combating resistant fungal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.